Tag: SentreHeart

AtriCure Enters Into Definitive Agreement to Acquire SentreHEART

Acquisition Expands Addressable Market Opportunity and Complements Offerings for the Treatment of Atrial Fibrillation Announces Updates to 2019 Outlook Conference Call Monday, August 12th at 8:30am ET MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that […]

SentreHEART Announces Initial Clinical Use of the LARIAT® with EpiRAIL™ Procedure for Left Atrial Appendage Exclusion

REDWOOD CITY, Calif.–(BUSINESS WIRE)–SentreHEART, Inc., announced it has successfully completed nine First-In-Human procedures utilizing the LARIAT® with EpiRAIL™ at John Paul II hospital in Krakow, Poland. The LARIAT with EpiRAIL is an epicardial-only, percutaneous approach to complete and permanent closure of the left atrial appendage (LAA) in patients with atrial fibrillation […]

SentreHEART Receives CE Mark for LARIAT-RS™ 50mm and Expanded Indication for Left Atrial Appendage Exclusion

REDWOOD CITY, Calif.–(BUSINESS WIRE)–SentreHEART, Inc., announced it has received CE Mark for the LARIAT-RS™ 50mm as well as expanded labeling for the LARIAT-RS for left atrial appendage (LAA) exclusion. The new 50mm device along with the 45mm LARIAT-RS is now available for sale in Europe. The LARIAT-RS (LARIAT) device is […]

SentreHEART Announces 400th Patient Enrollment in the Landmark aMAZE Trial

REDWOOD CITY, Calif.–(BUSINESS WIRE)–SentreHEART, Inc., manufacturer of the LARIAT® Suture Delivery Device (LARIAT) for percutaneous left atrial appendage (LAA) closure announces enrollment of the 400th patient in the prospective, multi-center, randomized controlled Trial known as the aMAZE Trial. The Trial is a superiority design and intends to demonstrate the LARIAT procedure […]

SentreHEART Announces Participation at The American College of Cardiology’s 67th Annual Scientific Session & Expo

REDWOOD CITY, Calif.–(BUSINESS WIRE)–SentreHEART, Inc., the manufacturer of the LARIAT® Suture Delivery Device (LARIAT) will be participating in the American College of Cardiology (ACC) 2018 meeting being held in Orlando, Florida, March 10-12, 2018. The meeting’s agenda includes several sessions dedicated to exploring device-based options for Left Atrial Appendage (LAA) […]

SentreHEART Announces Participation at International AF Symposium 2018

REDWOOD CITY, Calif.–(BUSINESS WIRE)–SentreHEART, Inc., the manufacturer of the LARIAT® Suture Delivery Device (LARIAT) will be participating in the 23rd Annual International AF Symposium being held in Orlando, FL, January 11- 13, 2018. The symposium’s agenda will include several sessions dedicated to exploring device-based options for Left Atrial Appendage (LAA) closure […]

SentreHEART Announces Participation at American Heart Association Scientific Sessions 2017

REDWOOD CITY, Calif.–(BUSINESS WIRE)– SentreHEART, Inc., the manufacturer of the LARIAT® Suture Delivery Device (LARIAT) will be participating in the American Heart Association (AHA) Scientific Sessions 2017 in Anaheim, California November 11-15, 2017. AHA’s Scientific Sessions attracts nearly 18,000 attendees, with a global presence from more than 100 countries. With a commitment to […]

SentreHEART Announces Participation at Transcatheter Cardiovascular Therapeutics 2017

REDWOOD CITY, Calif.–(BUSINESS WIRE)–SentreHEART, Inc., the manufacturer of the LARIAT® Suture Delivery Device (LARIAT) will be participating in the Transcatheter Cardiovasular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, in Denver, CO October 29 – November 2, 2017. The symposium’s agenda will include several sessions dedicated to […]